Jump to content

Harrison Stafford

Legacy Members
  • Posts

    2912
  • Joined

  • Last visited

Everything posted by Harrison Stafford

  1. AMYZF is now revenue producing with more to come. Ditto on the $10. I have 125,000 shares and when it hits that sp, I’ll rent a party room in Austin and drinks are on me.
  2. https://www.otcmarkets.com/stock/AMYZF/news/RecycLiCo-Taiwan-Battery-Recycling-Joint-Venture-Commences-Production-and-Sales-of-Black-Powder?id=446104 Why AMYZF is positive for the day.
  3. Will sell half the position at $10 and let the other half ride.
  4. I’d take a position in both IBRX and GERN. Both are biotechs and both have had cancer drugs recently approved by the FDA. IBRX’s Anktiva was approved on April 22 for the treatment of bladder cancer and IBRX began shipping Anktiva two weeks after approval. These sales should be reflected in IBRX’s Q2 earnings. As more and more healthcare plans allow for Anktiva reimbursement, earnings should continue to grow in each successive quarter for the foreseeable future as Anktiva becomes the standard of care for the treatment of bladder cancer. But, that’s just the start of the story. IBRX, per their website, met with the FDA in June to get the green light to use Anktiva for the treatment of 2nd line and 3rd line lung cancer. As Anktiva is already an approved drug for bladder cancer, label expansion is not usually as difficult as a new set of trials. IBRX also has ongoing trials using Anktiva in conjunction with other drugs/vaccines to treat colorectal cancer, ovarian cancer, pancreatic cancer, glioblastoma, and leukemia and all these are in phase 2 trials. There’s also phase 1 trials for HPV, advanced solid tumors, non-Hodgkin lymphoma, and HIV also marrying Anktiva with other drugs/vaccines as treatment. Go to ImmunityBio’s website Immunitybio.com and read about what this company is doing. GERN’s drug, Rytelo (formerly Imetelstat), was approved on June 6 and is used for treating transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS), a group of blood cancers. I think GERN is a big time takeover target and (if there’s a buyout) goes at 4x the current sp. Maybe more. If Big Pharma won’t pony up the big $$ to buy GERN, I still expect the sp to go much higher as Rytelo sales start to come in and the drug is approved in additional indications (mainly MF and AML). Buyout or no buyout, you should make money…unless something comes out of left field that is completely unforeseen.
  5. We have a team that, potentially, can compete for the WS and we have a coach that’s a rookie.
  6. EOSE +.20 to $1.97. Volume today is already almost twice that of avg. daily volume.
  7. We don’t want any candy stripes on our uniforms. These are work clothes.” — Darrell Royal
  8. Living in a Van Down By The River?
  9. Oooooooh, I like.
  10. EOSE +.22 on the day. In a week, the stock has moved from .86 to $1.77. @Wally Fairway How about A Clockwork Orange?
  11. You’re being very kind and I’m flattered you would consider this, but until one of IBRX, UUUU, GERN, EOSE, RVPH, or AMYZF takes off and makes us some serious ca$h, there’s no reason to promote my picks or give me a catchy poster name more so than any other Surly poster. However, when that day comes, I kind of like the poster name Flying Chards of Glass.
  12. EOSE +.19 to $1.46.
  13. IBRX ytd $5.02 to $6.32 EOSE ytd $1.09 to $1.27 UUUU ytd $7.09 to $6.06 AMYZF ytd $.18 to $.08 RVPH ytd $5.15 to $1.28 GERN ytd $2.11 to $4.24 Still holding all positions. Will revisit in 6 months.
  14. Two weeks ago, we’d have found a way to lose this game. Not now, baby.
  15. I’ve got to admit it’s getting better.
  16. A man who could hang with New York’s elite and Texas trailer trash. I was fortunate enough to have a one on one conversation with the man for a good 30 minutes and, yeah, he got my vote.
  17. IBRX shorts only declined by a little over 27,000 shares. Still over 53.4 million sold short…about 33% of the float. The average daily volume has declined in the past month, so it’s now just over 11 days to cover. IBRX’s website says, “ Meeting scheduled with FDA in June to discuss path to registration filing of ANKTIVA plus checkpoint inhibitors in 2nd – and 3rd-line NSCLC patients whose cancer previously did not respond to checkpoint therapy.” If the FDA told IBRX they could market to 2nd and 3rd line NSCLC, it’s very possible we get an outstanding short squeeze.
  18. AMY has enough cash to be solvent for at least 3 1/2 years, but, yes, it’s dead money as lithium is in oversupply. Some analysis don’t think the lithium market will bottom until 2025. Hurry up and wait.
  19. If only she looked like Dolly Parton.
  20. He’ll get his fair share of looks playing for the Rockets. Kid can shoot the rock.
×
×
  • Create New...